Lipopeptide-based compound for use in the prevention and/or treatment of a liver disease or condition, wherein the lipopeptide-based compound comprises a peptide of the general formula X-P-Y-R o wherein P is the amino acid sequence NPLGF Xaa P (SEQ. ID NO: 1), wherein Xaa is F or L, more preferably F, X is an amino acid sequence having a length of m amino acids, wherein m is at least 4; Y is an amino sequence having a length of n amino acids, wherein n is 0 or at least 1; and wherein m + n ≥ 11; R is a C-terminal modification of said hydrophobic modified peptide, which is preferably a moiety that protects from degradation selected from amide, D-amino acid, modified amino acid, cyclic amino acid, albumin, natural and synthetic polymer, such as PEG, glycane, o is 0 or at least 1, wherein the peptide comprises 18 to 119 consecutive amino acids of the amino acid sequence with SEQ ID NO. 18, 19 or 20, or an amino acid sequence having at least 90% sequence identity (preferably at least 95% or 99% identity) to any of SEQ ID NOs. 18 to 20, and an N-terminal hydrophobic modification by acylation with myristoyl, palmitoyl or stearoyl, preferably with myristoyl, wherein said liver disease or condition is related to sodium taurocholate cotransporter polypeptide (NTCP)-mediated transport of compounds into hepatocytes, and is a liver involved metabolic disease selected from intrahepatic cholestasis, poisoning of the liver (by liver toxins) / hepatotoxicity, drug-induced cholestatic liver disease, hypercholesterolaemia, posthepatic cholestasis. P is the amino acid sequence NPLGF Xaa P (SEQ. ID NO: 1), wherein Xaa is F or L, more preferably F, X is an amino acid sequence having a length of m amino acids, wherein m is at least 4; Y is an amino sequence having a length of n amino acids, wherein n is 0 or at least 1; and wherein m + n ≥ 11; R is a C-terminal modification of said hydrophobic modified peptide, which is preferably a moiety that protects from degradation selected from amide, D-amino acid, modified amino acid, cyclic amino acid, albumin, natural and synthetic polymer, such as PEG, glycane, o is 0 or at least 1, wherein the peptide comprises 18 to 119 consecutive amino acids of the amino acid sequence with SEQ ID NO. 18, 19 or 20, or an amino acid sequence having at least 90% sequence identity (preferably at least 95% or 99% identity) to any of SEQ ID NOs. 18 to 20, and an N-terminal hydrophobic modification by acylation with myristoyl, palmitoyl or stearoyl, preferably with myristoyl, 18 to 119 consecutive amino acids of the amino acid sequence with SEQ ID NO. 18, 19 or 20, or an amino acid sequence having at least 90% sequence identity (preferably at least 95% or 99% identity) to any of SEQ ID NOs. 18 to 20, and an N-terminal hydrophobic modification by acylation with myristoyl, palmitoyl or stearoyl, preferably with myristoyl, wherein said liver disease or condition is related to sodium taurocholate cotransporter polypeptide (NTCP)-mediated transport of compounds into hepatocytes, and is a liver involved metabolic disease selected from intrahepatic cholestasis, poisoning of the liver (by liver toxins) / hepatotoxicity, drug-induced cholestatic liver disease, hypercholesterolaemia, posthepatic cholestasis.